Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

The European Commission approval was based on two Phase III trials showing Vyloy plus chemo improved survival outcomes versus chemo alone.

NEW YORK – Sensorion on Monday said that by year end it expects to complete dosing the first cohort of pediatric patients with congenital hearing loss with its gene therapy candidate SENS-501 in the ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...

At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...

Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined ...

Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...

The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...

A group of hospital systems are using the machine-learning model to guide decisions on who should be tested for high levels of lipoprotein(a).

If it can secure the funds, Oncolytics will advance the agent into a pivotal study, based on positive data from the Phase I BRACELET-1 trial.

The results, published in Nature, strengthen oncologists' understanding of Enhertu's clinical activity as a second-line ...

Phase I data presented at ESMO suggested that TORL-1-23 may have particularly strong activity in CLDN-positive advanced ...